{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000064","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.778615+00:00","generated_at":"2026-06-08T23:41:47.747676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio Q3 net loss $37.3M ($1.41/sh); imsidolimab Phase 3 GPP hits primary endpoint","bullets":["Net loss $37.3M ($1.41/sh) vs $33.5M ($1.18/sh) YoY; R&D spend rose to $30.9M.","Cash $453.3M at Sep 30, down $130.9M; reaffirms cash runway through year-end 2026.","Imsidolimab Phase 3 GPP: 53.3% achieved GPPPGA 0/1 vs 13.3% placebo (p=0.0131); out-license planned in 2024.","Initiated Phase 2b rosnilimab RA trial (420 pts); Phase 2 UC trial starting Q4 2023; top-line mid-2025 and H1 2026.","Collaboration revenue from Jemperli royalties $3.3M (vs $1.3M) helped offset net loss expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000064","json":"https://secwatch.observer/filing/0001370053-23-000064.json","markdown":"https://secwatch.observer/filing/0001370053-23-000064.md","text":"https://secwatch.observer/filing/0001370053-23-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000064/0001370053-23-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000064/anab-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:41:47.747676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}